Ben Lamm's Warhound emerges from stealth to genetically engineer military dogs — dire wolves and beyond

Warhound's Military Bioengineering Bet: Dire Wolves and the $50M Dog Market

Ben Lamm, the de-extinction founder behind Colossal Biosciences, has launched Warhound out of stealth with Palmer Luckey (Anduril's founder) involved in the project. The company is pursuing genetically engineered animals for military and law enforcement applications, with ambitions that extend well beyond conventional dog breeding.

The core pitch centers on weaponizable biology. Lamm describes the appeal of 600-pound dire wolves—extinct canines engineered with modern obedience traits—as military units. A dire wolf carrying 150 pounds of armor would weigh roughly eight times more than a German Shepherd with 100 times greater bullet resistance, according to his framing. The concept isn't pure science fiction: the US military already deploys dolphins, seals, and working dogs. Warhound's angle is engineering these animals for enhanced endurance, high-altitude breathing, and Arctic wolf survival traits while preserving domestication.

The valuation math doesn't match the ambition. According to commentary on the segment, Warhound has raised $200 million at a $1.2 billion valuation against a current addressable market of $50 million annually in combined police and military dog breeding revenue. That represents a 24x funding multiple on existing market size—a bet that genetically engineered animals will open entirely new use cases rather than simply displace traditional breeding.

The hosts acknowledge this as a classic venture play: high-risk, high-reward capital deployed on a science experiment with longer time horizons. The skepticism is practical rather than technical. Retrofitting dire wolves for military use is plausible; building a consumer market for 10,000-pound dogs (à la Clifford the Big Red Dog) runs into hard constraints around housing, feeding costs, and actual demand. The US pet industry is worth $165 billion annually, which one speaker extrapolates as a potential trillion-dollar addressable market if engineered animals achieve retail viability—though that inference stretches well beyond current commercial reality.

The company's defensive applications are concrete. The consumer upside is speculative.